A yau a Rasha fiye da 10 ml na mutanen da ke da ciwon sukari suna rajista. Irin wannan cutar tana haɓaka asalin yanayin rashi insulin da ke tattare da tafiyar matakai na rayuwa.
Ga yawancin marasa lafiya, ana nuna insulin yau da kullun don cikakken rayuwa. Koyaya, a yau akan kasuwar likita fiye da 90% na dukkanin shirye-shiryen insulin ba a samar da su a cikin Federationungiyar Rasha ba. Me yasa haka yake faruwa, saboda kasuwar samar da insulin abu ne mai fa'ida sosai kuma ana mutunta shi?
A yau, samar da insulin a cikin Rasha a cikin yanayin jiki shine 3.5%, kuma a cikin kuɗin kuɗi - 2%. Kuma duka kasuwannin insulin ana kimanta dala miliyan 450-500. Daga cikin wannan adadin, miliyan 200 insulin ne, sauran kuma ana kashe su ne akan gwaje-gwaje (kusan miliyan 100) da allunan hailala (miliyan 130).
Ma'aikatan insulin na cikin gida
Tun daga 2003, ƙwayar insulin ta Medsintez ta fara aiki a Novouralsk, wanda a yau yana samar da kusan kashi 70% na insulin ɗin da ake kira Rosinsulin.
Ana yin samarwa a cikin ginin 4000 m2, wanda ke da tsabtattun wurare 386 m2. Hakanan, shuka tana da wuraren koyar da azuzuwan tsabta D, C, B da A.
Mai ƙera yana amfani da fasaha na zamani da kayan aiki na zamani daga sanannun kamfanonin kasuwanci. Wannan Jafananci (EISAI) Jamusanci (BOSCH, SUDMO) da kayan Italiya.
Har zuwa 2012, abubuwan da ake buƙata don samar da insulin sun sami ƙasashen waje. Amma kwanan nan, Medsintez, ya ƙirƙira kansa nau'in ƙwayoyin cuta kuma ya fito da maganinsa wanda ake kira Rosinsulin.
Dakatarwa ana yin shi a cikin kwalabe da katako na nau'ikan guda uku:
- P - maganin injiniyan ɗan adam don allura. Inganci bayan minti 30. bayan gudanarwa, mafi girman tasiri yana faruwa awanni 2-4 bayan allurar kuma zai iya zuwa awa 8.
- C - insulin-isophan, wanda akayi nufin sc gwamnati. Tasirin hypoglycemic yana faruwa ne bayan sa'o'i 1-2, ana samun mafi girman hankali bayan sa'o'i 6-12, kuma tsawon lokacin tasirin ya kasance har zuwa awanni 24.
- M - Rosinsulin kashi biyu na mutum don sc gwamnatin. Tasirin rage yawan sukari yana faruwa bayan mintina 30, kuma yawan taro yana faruwa ne cikin awanni 4-12 kuma ya kai zuwa awanni 24.
Baya ga waɗannan nau'ikan sashi, Medsintez ya samar da nau'ikan nau'ikan sirinji na Rosinsulin - wanda aka ƙaddamar da sake amfani dashi. Suna da kayan aikin mallaka na musamman da suke ba ku damar dawo da sigar da ta gabata idan ba a saita ta kamar yadda ya kamata ba.
Rosinsulin yana da sake dubawa da yawa a tsakanin marasa lafiya da likitoci. Ana amfani dashi idan akwai nau'in 1 ko type 2 diabetes, ketoacidosis, coma or diabetes. Wasu marasa lafiya suna da'awar cewa bayan gabatarwarsa, tsalle-tsalle a cikin sukari na jini ya faru, wasu masu ciwon sukari, akasin haka, suna yaba wannan magani, suna tabbatar da cewa yana ba ku damar iya sarrafa glycemia sosai.
Hakanan, tun daga 2011, aka fara samar da kayan aikin insulin na farko a Yankin Oryol, wanda ke aiwatar da cikakken sake zagayowar, yana samar da alkalannin sirinji cike da dakatarwa. Kamfanin Sanofi na kasa da kasa ya aiwatar da wannan aikin, wanda shine babban mai siyar da magunguna waɗanda ke maganin cututtukan sukari yadda ya kamata.
Koyaya, shuka ba ya samar da abubuwan da kansu. A cikin bushewa, ana siyar da kayan a cikin Jamus, bayan haka hormone na ɗan adam, analoginta da sauran abubuwan taimako don haɗuwa don samun abubuwan dakatarwa don yin allura. Don haka, ana yin aikin insulin na Rasha a Orel, lokacin da ake kera abubuwan insulin na sauri da tsawaita aiki, ingancin wanda ya dace da dukkan bukatun reshen Jamusawa.
WHO ta ba da shawarar a cikin kasashen da ke da yawan mutane sama da miliyan 50 don tsara nasu samar da kwayoyin. Wannan zai taimaka wa masu ciwon sukari basu da matsala sayen insulin.
Bugu da kari, Geropharm, shugaba ne kan haɓaka magungunan ƙwararrun jini a Rasha. Bayan haka, kawai wannan masana'anta suna samar da samfuran gida a cikin nau'ikan ƙwayoyi da abubuwa.
Wadannan magungunan sanannu ne ga duk wanda ke da ciwon sukari. Waɗannan sun haɗa da Rinsulin NPH (tasirin matsakaici) da Rinsulin P (gajeren aiki). An gudanar da binciken ne da nufin tantance tasirin wadannan kwayoyi, a yayin da aka sami karancin banbanci tsakanin amfani da insulin cikin gida da kuma magungunan kasashen waje.
Sabili da haka, masu ciwon sukari na iya amincewa da insulin na Rasha ba tare da damuwa da lafiyar su ba.
Shin magungunan kasashen waje zasu iya maye gurbin insulin cikin gida?
An aiwatar da cikakkiyar zagayen samar da magunguna na ilimin halittar jini bisa asalin Cibiyar Nazarin Kwayoyin Kimiya ta Moscow ta Kwalejin Kimiyya ta Rasha a Obolensk. Amma wannan samarwa ne mai ƙarancin wutar lantarki, ƙari ga wannan, kayan an kunshe su cikin kwantena marasa dacewa waɗanda basu dace da amfanin gida ba. Haka kuma, kamfanin ba ya samar da magungunan da ke da tasirin gaske.
Game da Medsintez da Pharmastandart, waɗannan masu samar da insulin suna tattara samfuran shigo da su. Farashin su kusan iri ɗaya yake da farashin kayayyakin ƙasar waje.
Koyaya, a yau wasu kamfanonin magunguna na Rasha suna shirye don shiga cikin cikakken samar da shirye-shiryen insulin. Hakanan ana shirin gina tsiro a cikin yankin Moscow, inda za a samar da nagartattun magunguna da na zamani waɗanda za su kula da masu cutar siga sosai. Don haka, har tsawon shekara guda mai ƙirar zai samar da kilogiram 250 na abubuwa.
Ana tunanin cewa samar da insulin na namu wanda zai kasance ne a shekarar 2017. Wannan zai ba mutane masu ciwon sukari damar siyan insulin na Rasha masu rahusa. Akwai wasu fa'idodi na haɓaka magungunan cikin gida:
- Da farko dai, tsire-tsire masu magunguna za su fara samar da kwayoyin halittu na tsawan lokaci da aikin ultrashort.
- A cikin shekaru 34 masu zuwa, ana shirin ƙaddamar da cikakken layin dukkan matsayi 4.
- Za a samu hodar ta jikin ta fannoni daban-daban - za'a sake amfani da sirinji da alkalami, alkalami, kwalabe da katukan katako.
Amma irin wannan tsari yana da tsayi. Saboda haka, insulin a Rasha ba da daɗewa ba zai iya maye gurbin magunguna da aka shigo da su.
A hanyar, Novo Nordisk (43.4%), Eli Lilly (27.6%) da Sanofi-Aventis (17.8%) sun kasance manyan kamfanoni a kasuwannin duniya da na Rasha.
Pharmstandard yana cikin wuri na huɗu akan wannan jerin (6%), yayin da sauran masana'antun suna kama kawai 3% na samar da insulin a cikin Rasha.
Fitar da insulin na Rasha zuwa Turai
Tun daga shekara ta 2016, kamfanin Sanofi (Faransa) yana da damar fitar da magungunan rigakafin cutar ta Rasha zuwa Jamus. Ana yin aikin insulin a cikin yankin Oryol a shuka na Sanofi-Aventis Vostok.
Yana da mahimmanci a lura cewa kashi na uku na kasuwar insulin (18.7%) shine mallakar Sanofi Russia. A lokaci guda, darektan kungiyar, Victoria Yeremina, ta ce masu ciwon sukari da ke zaune a Rasha ba su da wata damuwa game da su, saboda kayayyaki zuwa kasuwar Rasha na gida ba za su ragu ba, duk da karuwar fitar da insulin zuwa Turai.
Wannan zai iya yiwuwa saboda ƙarin karuwa a yawan samarwa. Lallai, masana'antar Sanofi Oryol tana da sabbin kayan aiki da kayan fasahar samarwa. Sabili da haka, samfurin insulin Glargin Lantus daga Sanofi yana ɗaukar matsayi na gaba a cikin siyarwar insulin a cikin kasuwar Rasha.
Don haka, insulin zai zama farkon samfuran Rasha na Sanofi da za a fitarwa. Ga kamfanin Faransa, irin wannan maganin yana da ma'ana kuma yana da fa'ida tattalin arziƙi, tunda kafin rikicin, farashin samar da magunguna a Turai da Rasha kusan iri ɗaya ne, amma bayan hakan samar da insulin ya zama 10-15% mai rahusa. Kuma haɓaka ƙarancin samar da kayayyaki zai rage farashin kayayyaki.
Bidiyo a cikin wannan labarin yayi magana game da samar da insulin a Rasha.
